MCID: NRL004
MIFTS: 48

Neuroleptic Malignant Syndrome

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Neuroleptic Malignant Syndrome

MalaCards integrated aliases for Neuroleptic Malignant Syndrome:

Name: Neuroleptic Malignant Syndrome 12 75 53 54 59 37 55 44 15 17 72

Characteristics:

Orphanet epidemiological data:

59
neuroleptic malignant syndrome
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:14464
KEGG 37 H01528
ICD9CM 35 333.92
MeSH 44 D009459
NCIt 50 C94829
SNOMED-CT 68 15244003 68977009
ICD10 33 G21.0
MESH via Orphanet 45 D009459
ICD10 via Orphanet 34 G21.0
UMLS via Orphanet 73 C0027849
Orphanet 59 ORPHA94093
UMLS 72 C0027849

Summaries for Neuroleptic Malignant Syndrome

KEGG : 37
Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening sideeffect to antipsychotic drugs characterized by fever, altered mental status, muscle rigidity, and autonomic dysfunction. NMS is classically associated with the use of high-potency antipsychotics (AP), such as butyrophenones and phenothiazines, but has also been described with newer agents, commonly described as atypical AP (risperidone, olanzapine, quetiapine), other D2-receptor antagonists (metoclopramide), and following withdrawal of anti dopaminergic agents. Although the precise pathophysiologic mechanism underlying NMS remains unknown, a reduction in dopaminergic activity in the brain probably by dopamine D2 receptor blockade in the striatum and hypothalamus is generally assumed as a potential cause. Laboratory findings include elevation of serum creatine phosphokinase (CK), liver enzymes, and leukocitosis. Treatment includes immediately stopping the offending agent and implementing supportive measures, as well as pharmacological interventions in more severe cases.

MalaCards based summary : Neuroleptic Malignant Syndrome is related to acute kidney failure and malignant hyperthermia. An important gene associated with Neuroleptic Malignant Syndrome is PIK3C2A (Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Alpha). The drugs Dopamine and Haloperidol have been mentioned in the context of this disorder. Affiliated tissues include brain, kidney and liver, and related phenotypes are hyperhidrosis and fever

Disease Ontology : 12 A nervous system disease that is characterized by hyperthermia, muscular rigidity, autonomic dysfunction and altered consciousness and is associated with administration of antipsychotic and other central dopaminergic blockers.

NIH Rare Diseases : 53 Neuroleptic malignant syndrome is a rare neurological condition that is caused by an adverse reaction to neuroleptic (tranquilizer) or antipsychotic drugs. These drugs are commonly prescribed for the treatment of schizophrenia and other neurological, mental, or emotional disorders. Affected people may experience high fever, muscle stiffness, sweating, unstable blood pressure, altered mental status, and autonomic dysfunction. In most cases, the condition develops within the first 2 weeks of treatment with the drug; however, it may develop any time during the therapy period. The exact underlying cause of neuroleptic malignant syndrome is unknown. In some cases, more than one family member can be affected which suggests there may be a genetic component. Upon diagnosis of the condition, the neuroleptic or antipsychotic drug is generally discontinued under a physician's supervision. Medications and/or other interventions may also be recommended to manage symptoms.

NINDS : 54 Neuroleptic malignant syndrome is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. Symptoms include high fever, sweating, unstable blood pressure, stupor, muscular rigidity, and autonomic dysfunction. In most cases, the disorder develops within the first 2 weeks of treatment with the drug; however, the disorder may develop any time during the therapy period. The syndrome can also occur in people taking anti-Parkinsonism drugs known as dopaminergics if those drugs are discontinued abruptly.

Wikipedia : 75 Neuroleptic malignant syndrome (NMS) is a life-threatening reaction that can occur in response to... more...

Related Diseases for Neuroleptic Malignant Syndrome

Diseases related to Neuroleptic Malignant Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)
# Related Disease Score Top Affiliating Genes
1 acute kidney failure 31.1 PIK3C2A MB
2 malignant hyperthermia 31.0 RYR1 PIK3C2A MB
3 tardive dyskinesia 31.0 DRD2 CYP2D6
4 myoglobinuria 31.0 PIK3C2A MB
5 serotonin syndrome 31.0 HTR1A CYP2D6
6 disseminated intravascular coagulation 30.7 PIK3C2A MB
7 gastroparesis 30.4 DRD2 CYP2D6
8 galactorrhea 30.3 DRD2 CYP2D6
9 gas gangrene 30.3 PIK3C2A MB
10 plexopathy 30.2 PIK3C2A MB
11 psychotic disorder 30.0 HTR1A DRD2 CYP2D6
12 mental depression 30.0 HTR1A CYP2D6
13 parkinson disease, late-onset 29.8 HTR1A DRD2 CYP2D6
14 substance abuse 29.7 DRD2 CYP2D6
15 obsessive-compulsive disorder 29.7 HTR1A DRD2 CYP2D6
16 compartment syndrome 29.6 PIK3C2A MB CHKB
17 major depressive disorder 29.6 HTR1A DRD2 CYP2D6
18 generalized anxiety disorder 29.6 HTR1A DRD2
19 acute myocardial infarction 29.4 PIK3C2A MB CHKB
20 attention deficit-hyperactivity disorder 29.3 HTR1A DRD2 CYP2D6
21 creatine phosphokinase, elevated serum 29.2 PIK3C2A MB CHKB
22 muscular dystrophy 28.3 RYR1 PIK3C2A CHKB
23 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.8
24 autonomic dysfunction 10.7
25 tremor 10.7
26 subacute delirium 10.6
27 ocular motor apraxia 10.5
28 major affective disorder 8 10.5
29 major affective disorder 9 10.5
30 bipolar disorder 10.5
31 kidney disease 10.5
32 schizoaffective disorder 10.5
33 mutism 10.4
34 encephalitis 10.4
35 respiratory failure 10.4
36 dystonia 10.4
37 isolated hyperckemia 10.4
38 virus associated hemophagocytic syndrome 10.4 PIK3C2A MB
39 paranoid schizophrenia 10.4
40 delusional disorder 10.4 DRD2 CYP2D6
41 interstitial myocarditis 10.4 PIK3C2A MB
42 myoclonus 10.4
43 posterior myocardial infarction 10.3 PIK3C2A MB
44 myositis fibrosa 10.3 PIK3C2A MB
45 anuria 10.3 PIK3C2A MB
46 intermediate coronary syndrome 10.3 PIK3C2A MB
47 dysphagia 10.3
48 encephalopathy 10.3
49 acute mountain sickness 10.3 PIK3C2A MB
50 pseudohyperkalemia, familial, 2, due to red cell leak 10.3 PIK3C2A MB

Graphical network of the top 20 diseases related to Neuroleptic Malignant Syndrome:



Diseases related to Neuroleptic Malignant Syndrome

Symptoms & Phenotypes for Neuroleptic Malignant Syndrome

Human phenotypes related to Neuroleptic Malignant Syndrome:

59 32 (show top 50) (show all 56)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000975
2 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
3 extrapyramidal muscular rigidity 59 32 hallmark (90%) Very frequent (99-80%) HP:0007076
4 mutism 59 32 hallmark (90%) Very frequent (99-80%) HP:0002300
5 abnormal autonomic nervous system physiology 59 32 hallmark (90%) Very frequent (99-80%) HP:0012332
6 tremor 59 32 frequent (33%) Frequent (79-30%) HP:0001337
7 dysphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002015
8 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
9 leukocytosis 59 32 frequent (33%) Frequent (79-30%) HP:0001974
10 metabolic acidosis 59 32 frequent (33%) Frequent (79-30%) HP:0001942
11 tachycardia 59 32 frequent (33%) Frequent (79-30%) HP:0001649
12 drooling 59 32 frequent (33%) Frequent (79-30%) HP:0002307
13 muscle spasm 32 frequent (33%) HP:0003394
14 elevated serum creatine kinase 32 frequent (33%) HP:0003236
15 chorea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002072
16 hypotension 59 32 occasional (7.5%) Occasional (29-5%) HP:0002615
17 proteinuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000093
18 dehydration 59 32 occasional (7.5%) Occasional (29-5%) HP:0001944
19 vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002013
20 hyperuricemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002149
21 pulmonary embolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0002204
22 nasogastric tube feeding 59 32 occasional (7.5%) Occasional (29-5%) HP:0040288
23 anxiety 59 32 occasional (7.5%) Occasional (29-5%) HP:0000739
24 elevated hepatic transaminase 59 32 occasional (7.5%) Occasional (29-5%) HP:0002910
25 agitation 59 32 occasional (7.5%) Occasional (29-5%) HP:0000713
26 coma 59 32 occasional (7.5%) Occasional (29-5%) HP:0001259
27 hypocalcemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002901
28 hypertensive crisis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100735
29 thrombocytosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001894
30 increased lactate dehydrogenase activity 59 32 occasional (7.5%) Occasional (29-5%) HP:0025435
31 hyponatremia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002902
32 hyperkalemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002153
33 acute kidney injury 59 32 occasional (7.5%) Occasional (29-5%) HP:0001919
34 urinary incontinence 59 32 occasional (7.5%) Occasional (29-5%) HP:0000020
35 encephalopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001298
36 nausea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002018
37 hyperphosphatemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002905
38 myoglobinuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0002913
39 rhabdomyolysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0003201
40 oculogyric crisis 59 32 occasional (7.5%) Occasional (29-5%) HP:0010553
41 elevated alkaline phosphatase 59 32 occasional (7.5%) Occasional (29-5%) HP:0003155
42 hypomagnesemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002917
43 delirium 59 32 occasional (7.5%) Occasional (29-5%) HP:0031258
44 rigors 59 32 occasional (7.5%) Occasional (29-5%) HP:0025145
45 aspiration pneumonia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011951
46 hypernatremia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003228
47 hypothermia 59 32 very rare (1%) Very rare (<4-1%) HP:0002045
48 thrombocytopenia 59 32 very rare (1%) Very rare (<4-1%) HP:0001873
49 sepsis 59 32 very rare (1%) Very rare (<4-1%) HP:0100806
50 bradycardia 59 32 very rare (1%) Very rare (<4-1%) HP:0001662

MGI Mouse Phenotypes related to Neuroleptic Malignant Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.55 CHKB DRD2 HTR1A NHLRC1 RYR1
2 homeostasis/metabolism MP:0005376 9.5 CHKB DRD2 HTR1A MB NHLRC1 PIK3C2A
3 muscle MP:0005369 9.02 CHKB DRD2 MB NHLRC1 RYR1

Drugs & Therapeutics for Neuroleptic Malignant Syndrome

Drugs for Neuroleptic Malignant Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
2
Haloperidol Approved Phase 3 52-86-8 3559
3
Dantrolene Approved, Investigational Phase 2, Phase 3 7261-97-4 2952 6914273
4 Antipsychotic Agents Phase 3
5 Tranquilizing Agents Phase 3
6 Central Nervous System Depressants Phase 3
7 Psychotropic Drugs Phase 3
8 Neurotransmitter Agents Phase 3
9 Gastrointestinal Agents Phase 3
10 Antiemetics Phase 3
11 Haloperidol decanoate Phase 3
12 Dopamine Agents Phase 3
13 Dopamine Antagonists Phase 3
14 Autonomic Agents Phase 3
15 Quetiapine Fumarate Phase 3 111974-72-2
16 Antidepressive Agents Phase 3
17 Peripheral Nervous System Agents Phase 2, Phase 3
18 Neuromuscular Agents Phase 2, Phase 3
19
Octreotide Approved, Investigational Phase 1, Phase 2 83150-76-9 383414 6400441
20
Prochlorperazine Approved, Vet_approved Phase 1, Phase 2 58-38-8, 1984-02-6 4917
21
Dexmedetomidine Approved, Vet_approved Phase 2 113775-47-6 68602 5311068
22 Antineoplastic Agents, Hormonal Phase 1, Phase 2
23 Analgesics Phase 2
24 Adrenergic Agonists Phase 2
25 Adrenergic alpha-2 Receptor Agonists Phase 2
26 Analgesics, Non-Narcotic Phase 2
27 Adrenergic alpha-Agonists Phase 2
28 Hypnotics and Sedatives Phase 2
29 Adrenergic Agents Phase 2
30
Acetaminophen Approved 103-90-2 1983
31
Ibuprofen Approved 15687-27-1 3672
32
Risperidone Approved, Investigational 106266-06-2 5073
33
Creatine Approved, Investigational, Nutraceutical 57-00-1 586
34 Lipid Regulating Agents
35 Clofibric Acid 882-09-7
36 Hydroxymethylglutaryl-CoA Reductase Inhibitors
37 Hypolipidemic Agents
38 Anticholesteremic Agents
39 Antimetabolites
40 Cyclooxygenase Inhibitors
41 Anti-Inflammatory Agents, Non-Steroidal
42 Antipyretics
43 Anti-Inflammatory Agents
44 Antirheumatic Agents
45 Serotonin Antagonists
46 Serotonin 5-HT2 Receptor Antagonists
47 Serotonin Agents
48 Paliperidone Palmitate
49 Dopamine D2 Receptor Antagonists
50
Serotonin Investigational, Nutraceutical 50-67-9 5202

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium : The Haloquet Trial Completed NCT01811459 Phase 3 Quetiapine;Haloperidol;Placebo
2 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
3 Dantrolene as a Treatment for Hyperthermia in Patients After Subarachnoidal Hemorrhage Terminated NCT00796900 Phase 2, Phase 3 Dantrolene;Placebo
4 Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache Unknown status NCT00274170 Phase 1, Phase 2 Octreotide
5 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia: a Randomized, Controlled, Double Blind, Two-armed Clinical Trial Completed NCT01176721 Phase 2
6 A Randomised Open Label Pilot Study of the Efficacy of Dexmedetomidine and Haloperidol in Ventilated Patients With ICU-associated Agitation and Delirium Completed NCT00505804 Phase 2 dexmedetomidine;haloperidol
7 Rhabdomyolysis - A Retrospective Study in Hospitalized Patients Unknown status NCT01022450
8 Effects of Preemptive Intravenous Paracetamol and Ibuprofen on Headache and Myalgia in Patients After Electroconvulsive Therapy Completed NCT03783312 placebo;paracetamol;ibuprofen
9 Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva Completed NCT00395499 Risperidone

Search NIH Clinical Center for Neuroleptic Malignant Syndrome

Inferred drug relations via UMLS 72 / NDF-RT 51 :


2-Bromoergocryptine Mesylate
Bromocriptine
Bromocriptine
Dantrolene
Dantrolene Sodium

Cochrane evidence based reviews: neuroleptic malignant syndrome

Genetic Tests for Neuroleptic Malignant Syndrome

Anatomical Context for Neuroleptic Malignant Syndrome

MalaCards organs/tissues related to Neuroleptic Malignant Syndrome:

41
Brain, Kidney, Liver, Heart, Hypothalamus, Testes, Subthalamic Nucleus

Publications for Neuroleptic Malignant Syndrome

Articles related to Neuroleptic Malignant Syndrome:

(show top 50) (show all 2143)
# Title Authors PMID Year
1
[Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up]. 9 38
20159196 2010
2
Neuroleptic malignant syndrome or a statin drug reaction? A case report. 9 38
19952877 2009
3
Neuroleptic malignant syndrome: a review and report of six cases. 9 38
17214072 2006
4
Massive creatine kinase elevations with quetiapine: report of two cases. 9 38
16453254 2006
5
[Importance of creatine kinase psychiatry--truths and myths]. 9 38
16813275 2006
6
CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report. 9 38
16048458 2005
7
Cardiac involvement in malignant syndrome in Parkinson's disease. 9 38
16145285 2005
8
Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. 9 38
12555236 2003
9
High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. 9 38
12006894 2002
10
Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. 9 38
11579007 2001
11
Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. 9 38
11204351 2000
12
Psychopharmacology research in the English-speaking Caribbean. 9 38
10820583 2000
13
Severe catatonia and neuroleptic malignant syndrome: report of 3 cases. 9 38
10561954 1999
14
CYP2D6 HhaI genotype and the neuroleptic malignant syndrome. 9 38
9892857 1999
15
Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes. 9 38
9734554 1998
16
Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. 9 38
9804127 1998
17
Neuroleptic malignant syndrome with risperidone. 9 38
9165568 1997
18
The obscure autopsy and neuroleptic malignant syndrome. 9 38
9029927 1997
19
Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B. 9 38
9323326 1997
20
[Neuroleptic malignant syndrome, syndrome malin]. 9 38
8904246 1996
21
The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. 9 38
8101383 1993
22
[Creatine phosphokinase in a hospitalized psychiatric population]. 9 38
1362345 1992
23
[The relationship between syndrome malin and neuroleptic malignant syndrome, and rhabdomyolysis]. 9 38
1970519 1990
24
Rhabdomyolysis and Neuroleptic Malignant Syndrome Associated with Very Low-dose Antipsychotics in Children and Adolescent. 38
31352714 2019
25
Catatonia After Neuroleptic Malignant Syndrome Successfully Treated With Electroconvulsive Therapy. 38
31424701 2019
26
A Case Report: Atypical Neuroleptic Malignant Syndrome on Clozapine and Mood Stabilizers. 38
31425460 2019
27
Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review. 38
31378552 2019
28
Clozapine Rechallenge Following Neuroleptic Malignant Syndrome: A Systematic Review. 38
31205196 2019
29
Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy. 38
31205194 2019
30
Takotsubo Cardiomyopathy: Medical and Psychiatric Aspects. Role of Psychotropic Medications in the Treatment of Adults with "Broken Heart" Syndrome. 38
31423403 2019
31
Electroconvulsive therapy for catatonia secondary to neuroleptic malignant syndrome in a patient with multiple sclerosis. 38
31072113 2019
32
Neuroleptic malignant syndrome in pregnancy: case report and literature review. 38
29363376 2019
33
Exertional Heatstroke in a Marathon Runner Complicated by Concurrent Use of an Antipsychotic Medication Affecting Thermoregulation. 38
31157624 2019
34
Neuroleptic malignant syndrome: a concealed diagnosis with multitreatment approach. 38
31213433 2019
35
Atypical neuroleptic malignant syndrome: A systematic review of case reports. 38
31299470 2019
36
Effect of Pharmacist Intervention on a Population in Taiwan with High Healthcare Utilization and Excessive Polypharmacy. 38
31234455 2019
37
The Role of Physical Examinations in Psychiatry as Illustrated in a Case of Neuroleptic Malignant Syndrome Versus Viral Encephalitis: A Case Report and Literature Review. 38
31410323 2019
38
Malignant deep brain stimulator withdrawal syndrome. 38
31092485 2019
39
Clinically Significant Drug-Drug Interactions Involving Medications Used for Symptom Control in Patients With Advanced Malignant Disease: A Systematic Review. 38
30776538 2019
40
Alcohol Withdrawal Mimicking Neuroleptic Malignant Syndrome. 38
31338272 2019
41
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report. 38
30501608 2019
42
Clinical utility of neutrophil-lymphocyte ratio in the diagnosis of neuroleptic malignant syndrome. 38
31164025 2019
43
Serum osmolarity and blood viscosity as a potential explanation for the pathophysiology of neuroleptic malignant syndrome. 38
31116616 2019
44
A Mixed Presentation of Serotonin Syndrome Versus Neuroleptic Malignant Syndrome in a 12-Year-Old Boy. 38
30964850 2019
45
Lifesaving Electroconvulsive Therapy for a Child With Autism Spectrum Disorder, Severe Self-Injurious Behavior, and Neuroleptic Malignant Syndrome. 38
31022044 2019
46
Long-Segment Myelitis, Meningoencephalitis, and Axonal Polyneuropathy in a Case of Scrub Typhus. 38
31007446 2019
47
Atypical neuroleptic malignant syndrome - A case report. 38
31071486 2019
48
Electroconvulsive Therapy for Neuroleptic Malignant Syndrome: A Case Series. 38
31022041 2019
49
A Case of Neuroleptic Malignant Syndrome in Pregnancy. 38
31114730 2019
50
A rare iatrogenic association of syndrome of inappropriate secretion of antidiuretic hormone, neuroleptic malignant syndrome and rhabdomyolysis. 38
30949348 2019

Variations for Neuroleptic Malignant Syndrome

Expression for Neuroleptic Malignant Syndrome

Search GEO for disease gene expression data for Neuroleptic Malignant Syndrome.

Pathways for Neuroleptic Malignant Syndrome

GO Terms for Neuroleptic Malignant Syndrome

Biological processes related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 release of sequestered calcium ion into cytosol GO:0051209 8.96 RYR1 DRD2
2 response to hypoxia GO:0001666 8.8 RYR1 MB DRD2

Molecular functions related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 8.62 DRD2 CYP2D6

Sources for Neuroleptic Malignant Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....